Please use this identifier to cite or link to this item:
|Title:||BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies|
|Authors:||Marciano, Beatriz E.|
Costa-Carvalho, Beatriz Tavares [UNIFESP]
Reda, Shereen M.
Franco, Jose L.
Gomez Raccio, Andrea C.
Grumach, Anete Sevciovic
Orellana, Julio C.
Mazzucchelli, Juliana T. L. [UNIFESP]
Vilela, Maria M. S. [UNIFESP]
Tavares, Fabiola S. [UNIFESP]
Pinto, Jorge A.
Espinosa-Padilla, Sara E.
Elfeky, Reem A.
Enriqueta Nunez-Nunez, M.
Marques, Jose Goncalo
Pereira, Maria I.
Slatter, Mary A.
Fleisher, Thomas A.
Rosenzweig, Sergio D.
Univ Tehran Med Sci
Universidade Federal de São Paulo (UNIFESP)
Great Ormond St Hosp Sick Children
Ain Shams Univ
Great North Childrens Hosp
Natl Inst Pediat
Natl Childrens Hosp Dr Carlos Saenz Herrera
Ctr Pediat Hematol Oncol & Immunol
Childrens Univ Hosp
Childrens Hosp Ricardo Gutierrez
Universidade de São Paulo (USP)
Hosp Santa Maria
Sultan Qaboos Univ Hosp
Ondokuz Mayis Univ
Santisima Trinidad Childrens Hosp
Tokyo Med & Dent Univ
Hyogo Coll Med
Univ Hong Kong
Kyoto Univ Hosp
Western Natl Med Ctr
Universidade Federal de Minas Gerais (UFMG)
Charles Univ Prague
Univ Hosp Motol
Hop Necker Enfants Malad
severe combined immunodeficiency
hematopoietic stem cell transplant
immune reconstitution syndrome
|Citation:||Journal of Allergy and Clinical Immunology. New York: Mosby-Elsevier, v. 133, n. 4, p. 1134-1141, 2014.|
|Abstract:||Background: Severe combined immunodeficiency (SCID) is a syndrome characterized by profound T-cell deficiency. BCG vaccine is contraindicated in patients with SCID. Because most countries encourage BCG vaccination at birth, a high percentage of patients with SCID are vaccinated before their immune defect is detected.Objectives: We sought to describe the complications and risks associated with BCG vaccination in patients with SCID.Methods: An extensive standardized questionnaire evaluating complications, therapeutics, and outcomes regarding BCG vaccination in patients given a diagnosis of SCID was widely distributed. Summary statistics and association analysis was performed.Results: Data on 349 BCG-vaccinated patients with SCID from 28 centers in 17 countries were analyzed. Fifty-one percent of the patients had BCG-associated complications, 34% disseminated and 17% localized (a 33,000- and 400-fold increase, respectively, over the general population). Patients receiving early vaccination (<= 3 1 month) showed an increased prevalence of complications (P = 5.006) and death caused by BCG-associated complications (P < .0001). the odds of experiencing complications among patients with T-cell numbers of 250/mu L or less at diagnosis was 2.1 times higher (95% CI, 1.4-3.4 times higher; P = .001) than among those with T-cell numbers of greater than 250/mL. BCG-associated complications were reported in 2 of 78 patients who received antimycobacterial therapy while asymptomatic, and no deaths caused by BCG-associated complications occurred in this group. in contrast, 46 BCG-associated deaths were reported among 160 patients treated with antimycobacterial therapy for a symptomatic BCG infection (P < .0001).Conclusions: BCG vaccine has a very high rate of complications in patients with SCID, which increase morbidity and mortality rates. Until safer and more efficient antituberculosis vaccines become available, delay in BCG vaccination should be considered to protect highly vulnerable populations from preventable complications.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.